SCRI Tissue Testing Registry

Study Overview
=================
Brief Summary
-----------------
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Detailed Description
-----------------
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions. This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).

Official Title
-----------------
SCRI Tissue Testing Registry

Conditions
-----------------
Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma

Intervention / Treatment
-----------------
* Other: Tissue Registry Study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be >= 18 years of age. Patients must be able to provide written informed consent. Exclusion Criteria: Not Applicable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. | Other: Tissue Registry Study<br>* If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing. |  | 120 months | 
| To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases |  | 120 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tissue Registry, Tissue Collection, Unknown Primary, Breast, Lung, Gastrointestinal, Bone Marrow Transplant, Chronic Lymphocytic Leukemia, Central Nervous System, Head and Neck, Melanoma, Myelodysplastic syndrome, Multiple Myeloma, Lymphoma, Gynecologic, Genitourinary, Refractory Malignancy